On Monday, Tscan Therapeutics Inc (NASDAQ: TCRX) was -7.41% drop from the session before settling in for the closing price of $1.08. A 52-week range for TCRX has been $0.91 – $4.85.
Annual sales at Healthcare sector company slipped by -14.41% over the past five years. When this article was written, the company’s average yearly earnings per share was at -5.49%. With a float of $46.42 million, this company’s outstanding shares have now reached $52.47 million.
Tscan Therapeutics Inc (TCRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tscan Therapeutics Inc stocks. The insider ownership of Tscan Therapeutics Inc is 18.20%, while institutional ownership is 56.93%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.29 earnings per share (EPS) during the time that was less than consensus figure (set at -0.28) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.18% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
You can see what Tscan Therapeutics Inc (TCRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.12, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.90 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc (NASDAQ: TCRX) saw its 5-day average volume 1.11 million, a positive change from its year-to-date volume of 0.54 million. As of the previous 9 days, the stock’s Stochastic %D was 50.81%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 5.42%, which indicates a significant decrease from 32.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1021 in the past 14 days, which was lower than the 0.1348 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6083, while its 200-day Moving Average is $1.6282. Nevertheless, the first resistance level for the watch stands at $1.1033 in the near term. At $1.2067, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3033. If the price goes on to break the first support level at $0.9033, it is likely to go to the next support level at $0.8067. Assuming the price breaks the second support level, the third support level stands at $0.7033.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
There are 56,748K outstanding shares of the company, which has a market capitalization of 56.75 million. As of now, sales total 2,820 K while income totals -127,500 K. Its latest quarter income was 2,510 K while its last quarter net income were -35,710 K.
